GlobeNewswire by notified

03/2023 Green Hydrogen Systems - Annual report 2022

Share

Company announcement 03/2023

Green Hydrogen Systems – Annual report 2022

Business highlights 2022

  • Successful acceptance test, delivery and revenue recognition of the first A90 electrolyser units
  • New orders of +5 MW in total with customers across multiple European countries
  • Total order backlog of 13 MW compared to 9.9 MW by the end of 2021
  • Development and assembly of the X-Series prototype progressed positively. Delivery to site targeted for March 2023
  • Expansion of new production facilities finalised. Assembly lines for the A-Series being established – X-Series assembly lines to follow from Q2 2023
  • The Board of Directors strengthened with industry competencies, Christian Clausen elected as new Chairman and a new ad-hoc Manufacturing & Technology Committee established to support product development and industrialisation of assembly process


Financial highlights 2022

  • Revenue from customer contracts of DKK 10 million (guidance: DKK 1 to 19 million) compared to DKK 5 million in 2021
  • Gross profit of DKK -10 million (guidance: around DKK -20 to -15 million) compared to DKK -17 million in 2021
  • EBITDA of DKK -249 million (guidance: DKK -255 to -235 million) compared to DKK -149 million in 2021
  • EBIT of DKK -283 million (guidance: DKK -290 to -270 million) compared to DKK -163 million in 2021
  • Investments of DKK 335 million (guidance: DKK 310 to 350 million) compared to DKK 192 million in 2021


Business events after 31 December 2022

  • New order of 16 A-Series pressurised alkaline electrolyser units with a combined capacity of 7.2 MW
  • Additional electrolyser units have been delivered to customers in the first two months of 2023 with more units to follow in the coming months
  • Mortgage loan granted for the new facilities at Nordager 21, Kolding amounting to DKK 120 million
  • New Chief Technology Officer, Stephan Kim and new Chief Operating Officer, Carsten Schütz joined Green Hydrogen Systems on 1 January 2023 and 1 March 2023 respectively


Guidance for 2023

Following successful acceptance tests and deliveries of A90 electrolyser units in December 2022, further deliveries in the first two months of 2023 and in the coming months as well as continued order backlog increase, Green Hydrogen Systems maintains the guidance for 2023 as announced 23 January 2023 (company announcement 02/2023):

  • Revenue, DKK 120 to 160 million
  • EBITDA, DKK -240 to -210 million
  • CAPEX, DKK 270 to 300 million

The revenue guidance range reflects the uncertainty of the exact timing of the electrolysers passing revenue recognition criteria within the 2023 calendar year. Furthermore, the exact delivery, site acceptance test (SAT), revenue recognition and EBITDA may be negatively impacted by e.g. the current supply chain disruptions, increasing component and raw material costs, general inflation, delays in product assembly and pandemics as well as delays and/or challenges at customer site not controlled by Green Hydrogen Systems.

Sebastian Koks Andreassen, CEO of Green Hydrogen Systems comments:

“Looking back, our company is in a significant improved position today compared to the same time last year.

During 2022 we matured our product offerings, executed on important customer deliveries, and progressed ahead of schedule on our manufacturing capacity expansion. We have continued to strengthen our organisational competencies across the company, and we see even more positive market developments thanwhat was the general industry expectations a year ago.

Our revenue for 2022 reached DKK 10 million and our investments were DKK 335 million. Both in line with our revised 2022 guidance range.

In 2023 we will continue to build on our competitive position by increasing sales and customer deliveries. We will also continue our investments in machinery and equipment to scale our manufacturing capacity and reap the benefits of the increasingly positive market prospects for pressurised alkaline electrolysers and green hydrogen.

We expect our revenue in 2023 to reach DKK 120 to 160 million with an investment level between DKK 270 to 300 million.

Furthermore, we target a capital increase of DKK 650 million through a rights issue with the proceeds supporting our continued production scaling efforts, our organisational competences and further strengthening of our balance sheet.

Conference call details

In connection with this announcement, Green Hydrogen Systems will host a conference call. The conference call will be held on 1 March 2023 at 10:00 AM CET.
Please visit investor.greenhydrogen.dk to access the presentation used for the meeting.

Link to the webcast

DK: +45 89 87 50 45
International dial-in: +44 20 3936 2999
Participant access code: 617256

Information regarding new Chief Technology Officer and new Chief Operating Officer

Stephan Kim is trained as a mechanical engineer and has performed a Doctorate / PhD with Fraunhofer IFAM in Germany. Stephan comes from a position as Chief Development & Innovation Officer and Member of the Executive Board with German medical technology company BEGO and with a prior career in science, technology, and project execution roles with Senvion, Airbus and Fraunhofer.

Carsten Schütz is trained as an aerospace engineer from University of Stuttgart. Carsten comes from a position as Vice President and Head of Production with the French aviation and aerospace company Airbus and with a prior career in engineering and technology roles with BAE Systems and Eurofighter Typhoon.

For more info please contact:

Investors:
Jens Holm Binger, Head of Investor Relations,
+45 6065 6525, jhb@greenhydrogen.dk

Media:
Jesper Buhl, Head of Public Affairs and Media Relations,
+45 5351 5295, jbu@greenhydrogen.dk

Forward-looking statements

This announcement contains forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘outlook’, ‘guidance’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Statements regarding the future are subject to risks and uncertainties that may result in considerable deviations from the outlook set forth. Furthermore, some of these expectations are based on assumptions regarding future events which may prove incorrect.

Please also refer to the overview of risk factors in the Annual Report 2022 available at greenhydrogen.dk.

Source: Green Hydrogen Systems
Ticker: GREENH
Tag: Company announcement

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Fortuna reports financial results for the first quarter of 20248.5.2024 04:11:05 CEST | Press release

(All amounts are expressed in US dollars, tabular amounts in millions, unless otherwise stated) VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) (“Fortuna” or the “Company”) today reported its financial and operating results for the first quarter of 2024. First Quarter 2024 highlights Financial Attributable net income of $26.3 million or $0.09 per share, compared to a $92.3 million attributable net loss or $0.30 per share in Q4 2023Adjusted attributable net income1 of $26.7 million or $0.09 per share, compared to $20.6 million or $0.07 per share in Q4 2023Generated $84.3 million of cash flow from operations before working capital changes, and free cash flow from ongoing operations1 of $12.1 million, compared to $105.4 million and $66.2 million, respectively, in Q4 2023The Company paid down $40.0 million of its revolving credit facility. At the close of the quarter total net debt was $83.0 million and the total net debt to ad

GXO Reports First Quarter 2024 Results7.5.2024 22:30:00 CEST | Press release

First quarter revenue of $2.5 billion, up 6% year over year; organic revenue growth1 of 1%Signed new business wins of approximately $250 million in annualized revenue in 1Q 2024; up 55% year over yearSales pipeline at 12-month high of $2.2 billionCompleted acquisition of Wincanton on April 29, 2024 GREENWICH, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- GXO Logistics, Inc. (NYSE: GXO) today announced results for the first quarter 2024. Malcolm Wilson, chief executive officer of GXO, said, “We delivered a strong start to 2024, reflecting our solid execution amid improving industry dynamics. The company grew revenue by 6% to $2.5 billion and delivered positive organic revenue growth, while gaining market share. We look forward to driving continued growth throughout 2024 and are on track to achieve our full-year outlook. “We’re seeing strengthening demand from global blue-chip customers to realize operational efficiencies today while planning fulfillment strategies to meet their future needs.

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update7.5.2024 22:30:00 CEST | Press release

Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent Business Developments Clinical and Regulatory Update Enrollment for VITESSE, DBV’s Phase 3 pivotal study of the modified Viaskin Peanut patch in children ages 4 through 7 years with peanut allergy passed the halfway point for recruitment in Q1 and continues to be on track to screen the last patient by

SFL - Invitation to Presentation of Q1 2024 Results7.5.2024 22:19:00 CEST | Press release

SFL Corporation Ltd. ("SFL" or the “Company”) (NYSE: SFL) plans to release its preliminary financial results for the first quarter of 2024 on Tuesday, May 14, 2024. SFL plans to host a conference call and webcast for all stakeholders and interested parties on Tuesday, May 14, 2024, at 10:00 AM (EST) / 4:00 PM (CET). Relevant material will on the same day be available from the Investor Relations section of the Company’s website at www.sflcorp.com. In order to listen to the conference call and presentation, you may do one of the following: A: Join Conference CallWebcast In Listen Only Mode: Visit the Investor Relations section of the Company’s website at www.sflcorp.com and click on the link to "Webcast", or access directly via the webcast link below. The webcast with slideshow will be played live from this platform: SFL Corporation Ltd. Q1 2024 Webcast B: Join Conference Call AndParticipate in Live Q&AthroughZoom: Join through the Zoom link below to ask a question: SFL Q1 2024 Q&A Meeti

Oculis Publishes Invitation to the Annual General Meeting7.5.2024 22:05:00 CEST | Press release

Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST / 9:30 a.m. EDT. All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website at https://investors.oculis.com/events-presentations. About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior

HiddenA line styled icon from Orion Icon Library.Eye